文献速递细菌感染、耐药与抗菌药物

全基因组测序在细菌抗菌药物敏感性检测中的作用:EUCAST小组委员会报告

The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee.
PubMed 文献 · Clin Microbiol Infect · 2016-11-23

EUCAST设立小组委员会评估全基因组测序(WGS)预测细菌抗菌药物敏感性(AST)的现状。报告指出目前支持WGS准确推断敏感性的已发表证据不足或缺乏,建议以流行病学折点作为基因型-表型一致性的主要比较指标、临床折点为次要指标,并呼吁统一质控标准与建立公共耐药位点数据库;对多数细菌而言,尚无足够证据支持用WGS推断的AST指导临床决策。

要点

  • 现有证据不足以支持WGS推断AST常规指导临床决策。
  • 基因型-表型一致性评估应首选流行病学折点,临床折点为次要。
  • 需统一质控指标、最低性能标准与公共耐药位点数据库。

核心结论

  • 目前用WGS准确推断抗菌药物敏感性的已发表证据不足或缺乏,证据与知识库需显著扩充。
  • 对多数细菌而言,尚无足够证据支持以WGS推断的AST指导临床决策。

研究设计与样本

  • 欧洲抗菌药物敏感性试验委员会(EUCAST)设立小组委员会,综述WGS用于细菌AST的当前发展状况。

主要发现

  • 评估WGS数据基因型-表型一致性的主要比较指标应改为流行病学折点,以区分野生型与非野生型(携带获得性耐药)分离株。
  • 临床折点应作为次要比较指标,据此判断遗传预测能否用于指导临床决策。

关键数值与推荐

  • 只有通过公认质控指标的数据库才可用于AST预测,且应存在最低性能标准并测量不同WGS实验室与流程间的比较准确性。
  • 应建立单一、定期更新并严格管理的全部已知耐药位点公共数据库,采用耐药位点纳入的最低标准。

临床怎么用

  • WGS-AST广泛用于临床的主要限制是当前高成本、从WGS数据推断敏感性的速度有限,以及依赖先前培养。
  • 直接对标本分析仍具挑战性。

局限性

  • 对多数细菌,支持WGS推断AST指导临床决策的证据不足。
  • WGS-AST若要与表型AST竞争,应成为资助优先事项;报告将随证据增加而更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whole genome sequencing (WGS) offers the potential to predict antimicrobial susceptibility from a single assay. The European Committee on Antimicrobial Susceptibility Testing established a subcommittee to review the current development status of WGS for bacterial antimicrobial susceptibility testing (AST). The published evidence for using WGS as a tool to infer antimicrobial susceptibility accurately is currently either poor or non-existent and the evidence / knowledge base requires significant expansion. The primary comparators for assessing genotypic-phenotypic concordance from WGS data should be changed to epidemiological cut-off values in order to improve differentiation of wild-type from non-wild-type isolates (harbouring an acquired resistance). Clinical breakpoints should be a secondary comparator. This assessment will reveal whether genetic predictions could also be used to guide clinical decision making. Internationally agreed principles and quality control (QC) metrics will facilitate early harmonization of analytical approaches and interpretive criteria for WGS-based predictive AST. Only data sets that pass agreed QC metrics should be used in AST predictions. Minimum performance standards should exist and comparative accuracies across different WGS laboratories and processes should be measured. To facilitate comparisons, a single public database of all known resistance loci should be established, regularly updated and strictly curated using minimum standards for the inclusion of resistance loci. For most bacterial species the major limitations to widespread adoption for WGS-based AST in clinical laboratories remain the current high-cost and limited speed of inferring antimicrobial susceptibility from WGS data as well as the dependency on previous culture because analysis directly on specimens remains challenging. For most bacterial species there is currently insufficient evidence to support the use of WGS-inferred AST to guide clinical decision making. WGS-AST should be a funding priority if it is to become a rival to phenotypic AST. This report will be updated as the available evidence increases.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Ellington MJ, Ekelund O, Aarestrup FM, et al. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect. 2016. PMID: 27890457. doi:10.1016/j.cmi.2016.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。